Abstract 989P
Background
Atezo-Bev is the one of the standard first-line treatments for pts with uHCC. There have been controversies that the efficacy of immune checkpoint inhibitors might be affected by the etiology of HCC. We performed a multinational retrospective study to investigate the impact of disease etiology on the efficacy outcomes with atezo-bev and prognostic factors in real-world uHCC pts treated with first line atezo-bev.
Methods
A total of 161 pts with Child A liver function who received first-line atezo-bev were included in the current analysis from Asan Medical Center (Seoul, Korea), and National Cancer Centre Singapore (Singapore), between July 2016 and July 2022. Pts with Child B liver function or prior systemic therapy were excluded. Tumor response was assessed per RECIST v1.1.
Results
The median age of the pts was 63 years (range, 16-90) and 136 pts (84.5%) were male. The most common etiology was hepatitis B virus (67.0%), followed by non-alcoholic fatty liver disease (NAFLD) (13.0%), alcohol (7.4%) and hepatitis C virus (4.3%). The objective response rate (ORR) of all pts was 23.6%. There was no difference in ORR based on etiology (viral vs non-viral, 22.1% vs 23.1%; NAFLD vs others, 21.1% vs 23.9%). With a median follow-up of 10.9 months(mo) (95% CI, 9.7-13.1), the median progression-free survival (PFS) and overall survival (OS) were 4.1 mo (95% CI, 3.1-6.9) and 14.0 mo (95% CI, 11.2-18.5), respectively. Median PFS and OS did not differ based on etiology (viral vs non-viral; PFS 4.4 vs 4.4 mo and OS, 14.0 vs 13.1 mo; NAFLD vs others; PFS 3.1 vs 4.1 mo and OS, 14.2 vs 14.0 mo). In the multivariable analysis, higher baseline NLR (≥2.5 [median]) was significantly associated with poorer PFS (median 3.8 vs 9.5 mo, HR 2.2, p=0.003) and OS (median 8.8 vs 27.0 mo, HR 5.0, p<0.001) compared to baseline NLR < 2.5. The most common adverse events (any grade) was hypertension (27.3%), followed by thrombocytopenia (16.9%), proteinuria (11.5%), and hemorrhage (11.5%).
Conclusions
Current study showed that disease etiology was not associated with the efficacy outcomes with first line atezo-bev in pts with uHCC, while higher NLR was a significant poor prognostic factor for these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.W.M. Tai: Financial Interests, Institutional, Advisory Board: Novartis, celgene, SIRTEX, MSD, BMS, Eisai, Bayer. C. Yoo: Financial Interests, Personal, Invited Speaker: Bayer, Celgene, Eisai, Ipsen, Servier, Roche, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Research Grant: AstraZeneca, Bayer, Servier; Financial Interests, Institutional, Research Grant: Genentech. All other authors have declared no conflicts of interest.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18